3/14 ApoL1 Long-Term Kidney Transplantation Outcomes Network (Apollo) Clinical Center

项目摘要 在撒哈拉以南非洲西部血统人群中常见的APOL1基因变异 与肾脏疾病有关，如局灶节段性肾小球硬化、高血压 归因于终末期肾病和艾滋病毒相关性肾病。两个人的存在 已故捐赠者的APOL1-肾脏风险变异(RRV)与风险增加2-4倍相关 受者的肾移植丢失的风险。携带APOL1风险等位基因的活体捐赠者可能面临肾脏风险 疾病。美国国立卫生研究院建立了“APOL1长期肾脏移植结果” 2017年阿波罗(Apollo)U01财团。阿波罗联盟包括13个临床中心 (CCS)与4个配对的核心中心研究APOL1的作用。约翰·霍普金斯/圣路易斯 大学CC是CC3。阿波罗联盟的主要目标是评估 全美接受AA捐赠者肾脏的患者的结果，或 其他最近有非洲血统的个体，并评估APOL1基因的相关性 与移植肾功能相关的预后。主要结果是移植物衰竭的时间。 收件人。其他结果包括受者肾功能改变率、 肾移植的急性排斥反应和蛋白尿。阿波罗联盟还确定 再生障碍性贫血活体供者(LDS)有意义的纵向结果，重点是生命状况和肾脏 功能，以及蛋白尿。虽然阿波罗加入了LDS，但他们的相对数字一直是 有限，强调需要更多的研究来更彻底地定义 APOL1基因与本应用寻求建立的长期LD结果之间的关系 并扩展阿波罗研究的发现，通过a)提供数据，为临床实践提供信息 载脂蛋白1基因对再生障碍性贫血肾移植受者预后的影响 捐赠者，b)提供关于APOL1基因对长期存活率的影响的数据 AA LDS及其受者的肾功能结局，以及c)建立临床资料来源 以及阿波罗联盟和其他未来的遗传数据和生物标本 研究人员通过NIDDK中央储存库。

Project Summary Genetic variants in APOL1 commonly found in people of Western Sub-Saharan Africa ancestry are associated with kidney diseases such as Focal Segmental Glomerulosclerosis, Hypertension Attributed-End Stage Kidney Disease, and HIV-Associated Nephropathy. The presence of 2 APOL1- renal risk variants (RRV) in deceased donors is associated with 2-to-4-times higher risk of renal graft loss in the recipient. Living donors with APOL1 risk alleles may be at risk for kidney disease. The NIH established the “APOL1 Long-term Kidney Transplantation Outcomes” (APOLLO) U01 Consortium in 2017. The APOLLO Consortium includes 13 clinical centers (CCs) with 4 paired core Centers to study the role of APOL1. The Johns Hopkins/Saint Louis University CC is CC3. The primary objectives of the APOLLO Consortium are to assess outcomes in patients across the entire United States who receive a kidney from an AA donor, or other individuals with recent African ancestry, and to evaluate the association of APOL1 genotype with renal allograft function-related outcomes. The primary outcome is time to graft failure in the recipients. Other outcomes include the rate of change of kidney function in recipients, rates of acute rejection of the kidney transplant, and proteinuria. The APOLLO Consortium also ascertains meaningful longitudinal outcomes in AA living donors (LDs), focusing on vital status and renal function, as well as proteinuria. While APOLLO enrolls LDs, their relative numbers have been limited, highlighting the need for additional studies designed to more thoroughly define the relationships of APOL1 genotype with long-term LD outcomes This application seeks to build on and extend the findings of the APOLLO study to inform clinical practice by a) providing data regarding the effects of APOL1 genotype on outcomes of the recipients of kidneys from AA donors, b) providing data regarding the effects of APOL1 genotype on long-term survival and renal functional outcomes of AA LDs and their recipients, and c) establishing a resource of clinical and genetic data and biological specimens for the APOLLO Consortium and other future researchers through the NIDDK Central Repository.